Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Gastrointestinal 3CNS 3Tumor-Agnostic 2Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2Dermatologic 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Melanoma 2

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Adjuvants, Immunologic × Dermatologic × Clear all
NCT04594187 2026-02-17

MelPORT

M.D. Anderson Cancer Center

Phase 2 Recruiting
168 enrolled
Dermatologic

Melanoma

NCT00365937 2019-03-06

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 1/2 Terminated
19 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡